Skip to main content
. 2021 Oct 18;125(12):1666–1676. doi: 10.1038/s41416-021-01560-1

Fig. 5. Elevated SLFN11 levels in HGSOC patients confers sensitivity to olaparib.

Fig. 5

a Cox proportional hazards model of progression-free survival (PFS) of high (>30 H-score SLFN11) vs. low SLFN11 ( ≤ 30 H-score SLFN11) subgroups in platinum-sensitive serous ovarian carcinoma patients treated with either placebo or olaparib. b Overall survival (OS) of high vs. low SLFN11 in the same study. Events table with patients at risk shown for each timepoint.